The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Direct-to-consumer Disease Risk and Health Test Market Research Report 2024

Global Direct-to-consumer Disease Risk and Health Test Market Research Report 2024

Publishing Date : Jan, 2024

License Type :
 

Report Code : 1715876

No of Pages : 105

Synopsis
The results of these tests estimate your genetic risk of developing several common diseases, such as celiac disease, Parkinson disease, and Alzheimer disease. Some companies also include a person’s carrier status for less common conditions, including cystic fibrosis and sickle cell disease. A carrier is someone who has one copy of a gene mutation that, when present in two copies, causes a genetic disorder.
The global Direct-to-consumer Disease Risk and Health Test market was valued at US$ 379 million in 2023 and is anticipated to reach US$ 1136.4 million by 2030, witnessing a CAGR of 17.0% during the forecast period 2024-2030.
The Direct-to-Consumer Genetic Testing Market is driven by the increasing consumer interest in understanding their genetic heritage, health risks, and ancestry. These tests provide individuals with accessible insights into their DNA, empowering them to make informed decisions about their health and heritage. Additionally, the ease of ordering these tests online and receiving results at home has made genetic testing more convenient and popular. However, a key challenge for this market is the need to address privacy and security concerns related to sensitive genetic data. Ensuring that consumer data is protected and not misused is a critical challenge. Furthermore, interpreting complex genetic information accurately can be a hurdle, as consumers may not fully understand the results or the potential implications. Striking a balance between accessibility and providing comprehensive education and genetic counseling is essential for the responsible growth of the Direct-to-Consumer Genetic Testing Market.
This report aims to provide a comprehensive presentation of the global market for Direct-to-consumer Disease Risk and Health Test, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Direct-to-consumer Disease Risk and Health Test.
Report Scope
The Direct-to-consumer Disease Risk and Health Test market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Direct-to-consumer Disease Risk and Health Test market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Direct-to-consumer Disease Risk and Health Test companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
23andMe
MyHeritage
LabCorp
Myriad Genetics
Ancestry.com
Quest Diagnostics
Gene By Gene
DNA Diagnostics Center
Invitae
IntelliGenetics
Ambry Genetics
Living DNA
EasyDNA
Pathway Genomics
Centrillion Technology
Xcode
Color Genomics
Anglia DNA Services
African Ancestry
Canadian DNA Services
DNA Family Check
Alpha Biolaboratories
Test Me DNA
23 Mofang
Genetic Health
DNA Services of America
Shuwen Health Sciences
Mapmygenome
Full Genomes
Segment by Type
Celiac Disease
Parkinson Disease
Alzheimer Disease
Other
Segment by Application
Online
Offline
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Direct-to-consumer Disease Risk and Health Test companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Direct-to-consumer Disease Risk and Health Test Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Celiac Disease
1.2.3 Parkinson Disease
1.2.4 Alzheimer Disease
1.2.5 Other
1.3 Market by Application
1.3.1 Global Direct-to-consumer Disease Risk and Health Test Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Online
1.3.3 Offline
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Direct-to-consumer Disease Risk and Health Test Market Perspective (2019-2030)
2.2 Direct-to-consumer Disease Risk and Health Test Growth Trends by Region
2.2.1 Global Direct-to-consumer Disease Risk and Health Test Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Direct-to-consumer Disease Risk and Health Test Historic Market Size by Region (2019-2024)
2.2.3 Direct-to-consumer Disease Risk and Health Test Forecasted Market Size by Region (2025-2030)
2.3 Direct-to-consumer Disease Risk and Health Test Market Dynamics
2.3.1 Direct-to-consumer Disease Risk and Health Test Industry Trends
2.3.2 Direct-to-consumer Disease Risk and Health Test Market Drivers
2.3.3 Direct-to-consumer Disease Risk and Health Test Market Challenges
2.3.4 Direct-to-consumer Disease Risk and Health Test Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Direct-to-consumer Disease Risk and Health Test Players by Revenue
3.1.1 Global Top Direct-to-consumer Disease Risk and Health Test Players by Revenue (2019-2024)
3.1.2 Global Direct-to-consumer Disease Risk and Health Test Revenue Market Share by Players (2019-2024)
3.2 Global Direct-to-consumer Disease Risk and Health Test Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Direct-to-consumer Disease Risk and Health Test Revenue
3.4 Global Direct-to-consumer Disease Risk and Health Test Market Concentration Ratio
3.4.1 Global Direct-to-consumer Disease Risk and Health Test Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Direct-to-consumer Disease Risk and Health Test Revenue in 2023
3.5 Direct-to-consumer Disease Risk and Health Test Key Players Head office and Area Served
3.6 Key Players Direct-to-consumer Disease Risk and Health Test Product Solution and Service
3.7 Date of Enter into Direct-to-consumer Disease Risk and Health Test Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Direct-to-consumer Disease Risk and Health Test Breakdown Data by Type
4.1 Global Direct-to-consumer Disease Risk and Health Test Historic Market Size by Type (2019-2024)
4.2 Global Direct-to-consumer Disease Risk and Health Test Forecasted Market Size by Type (2025-2030)
5 Direct-to-consumer Disease Risk and Health Test Breakdown Data by Application
5.1 Global Direct-to-consumer Disease Risk and Health Test Historic Market Size by Application (2019-2024)
5.2 Global Direct-to-consumer Disease Risk and Health Test Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Direct-to-consumer Disease Risk and Health Test Market Size (2019-2030)
6.2 North America Direct-to-consumer Disease Risk and Health Test Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Direct-to-consumer Disease Risk and Health Test Market Size by Country (2019-2024)
6.4 North America Direct-to-consumer Disease Risk and Health Test Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Direct-to-consumer Disease Risk and Health Test Market Size (2019-2030)
7.2 Europe Direct-to-consumer Disease Risk and Health Test Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Direct-to-consumer Disease Risk and Health Test Market Size by Country (2019-2024)
7.4 Europe Direct-to-consumer Disease Risk and Health Test Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Direct-to-consumer Disease Risk and Health Test Market Size (2019-2030)
8.2 Asia-Pacific Direct-to-consumer Disease Risk and Health Test Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Direct-to-consumer Disease Risk and Health Test Market Size by Region (2019-2024)
8.4 Asia-Pacific Direct-to-consumer Disease Risk and Health Test Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Direct-to-consumer Disease Risk and Health Test Market Size (2019-2030)
9.2 Latin America Direct-to-consumer Disease Risk and Health Test Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Direct-to-consumer Disease Risk and Health Test Market Size by Country (2019-2024)
9.4 Latin America Direct-to-consumer Disease Risk and Health Test Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Direct-to-consumer Disease Risk and Health Test Market Size (2019-2030)
10.2 Middle East & Africa Direct-to-consumer Disease Risk and Health Test Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Direct-to-consumer Disease Risk and Health Test Market Size by Country (2019-2024)
10.4 Middle East & Africa Direct-to-consumer Disease Risk and Health Test Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 23andMe
11.1.1 23andMe Company Detail
11.1.2 23andMe Business Overview
11.1.3 23andMe Direct-to-consumer Disease Risk and Health Test Introduction
11.1.4 23andMe Revenue in Direct-to-consumer Disease Risk and Health Test Business (2019-2024)
11.1.5 23andMe Recent Development
11.2 MyHeritage
11.2.1 MyHeritage Company Detail
11.2.2 MyHeritage Business Overview
11.2.3 MyHeritage Direct-to-consumer Disease Risk and Health Test Introduction
11.2.4 MyHeritage Revenue in Direct-to-consumer Disease Risk and Health Test Business (2019-2024)
11.2.5 MyHeritage Recent Development
11.3 LabCorp
11.3.1 LabCorp Company Detail
11.3.2 LabCorp Business Overview
11.3.3 LabCorp Direct-to-consumer Disease Risk and Health Test Introduction
11.3.4 LabCorp Revenue in Direct-to-consumer Disease Risk and Health Test Business (2019-2024)
11.3.5 LabCorp Recent Development
11.4 Myriad Genetics
11.4.1 Myriad Genetics Company Detail
11.4.2 Myriad Genetics Business Overview
11.4.3 Myriad Genetics Direct-to-consumer Disease Risk and Health Test Introduction
11.4.4 Myriad Genetics Revenue in Direct-to-consumer Disease Risk and Health Test Business (2019-2024)
11.4.5 Myriad Genetics Recent Development
11.5 Ancestry.com
11.5.1 Ancestry.com Company Detail
11.5.2 Ancestry.com Business Overview
11.5.3 Ancestry.com Direct-to-consumer Disease Risk and Health Test Introduction
11.5.4 Ancestry.com Revenue in Direct-to-consumer Disease Risk and Health Test Business (2019-2024)
11.5.5 Ancestry.com Recent Development
11.6 Quest Diagnostics
11.6.1 Quest Diagnostics Company Detail
11.6.2 Quest Diagnostics Business Overview
11.6.3 Quest Diagnostics Direct-to-consumer Disease Risk and Health Test Introduction
11.6.4 Quest Diagnostics Revenue in Direct-to-consumer Disease Risk and Health Test Business (2019-2024)
11.6.5 Quest Diagnostics Recent Development
11.7 Gene By Gene
11.7.1 Gene By Gene Company Detail
11.7.2 Gene By Gene Business Overview
11.7.3 Gene By Gene Direct-to-consumer Disease Risk and Health Test Introduction
11.7.4 Gene By Gene Revenue in Direct-to-consumer Disease Risk and Health Test Business (2019-2024)
11.7.5 Gene By Gene Recent Development
11.8 DNA Diagnostics Center
11.8.1 DNA Diagnostics Center Company Detail
11.8.2 DNA Diagnostics Center Business Overview
11.8.3 DNA Diagnostics Center Direct-to-consumer Disease Risk and Health Test Introduction
11.8.4 DNA Diagnostics Center Revenue in Direct-to-consumer Disease Risk and Health Test Business (2019-2024)
11.8.5 DNA Diagnostics Center Recent Development
11.9 Invitae
11.9.1 Invitae Company Detail
11.9.2 Invitae Business Overview
11.9.3 Invitae Direct-to-consumer Disease Risk and Health Test Introduction
11.9.4 Invitae Revenue in Direct-to-consumer Disease Risk and Health Test Business (2019-2024)
11.9.5 Invitae Recent Development
11.10 IntelliGenetics
11.10.1 IntelliGenetics Company Detail
11.10.2 IntelliGenetics Business Overview
11.10.3 IntelliGenetics Direct-to-consumer Disease Risk and Health Test Introduction
11.10.4 IntelliGenetics Revenue in Direct-to-consumer Disease Risk and Health Test Business (2019-2024)
11.10.5 IntelliGenetics Recent Development
11.11 Ambry Genetics
11.11.1 Ambry Genetics Company Detail
11.11.2 Ambry Genetics Business Overview
11.11.3 Ambry Genetics Direct-to-consumer Disease Risk and Health Test Introduction
11.11.4 Ambry Genetics Revenue in Direct-to-consumer Disease Risk and Health Test Business (2019-2024)
11.11.5 Ambry Genetics Recent Development
11.12 Living DNA
11.12.1 Living DNA Company Detail
11.12.2 Living DNA Business Overview
11.12.3 Living DNA Direct-to-consumer Disease Risk and Health Test Introduction
11.12.4 Living DNA Revenue in Direct-to-consumer Disease Risk and Health Test Business (2019-2024)
11.12.5 Living DNA Recent Development
11.13 EasyDNA
11.13.1 EasyDNA Company Detail
11.13.2 EasyDNA Business Overview
11.13.3 EasyDNA Direct-to-consumer Disease Risk and Health Test Introduction
11.13.4 EasyDNA Revenue in Direct-to-consumer Disease Risk and Health Test Business (2019-2024)
11.13.5 EasyDNA Recent Development
11.14 Pathway Genomics
11.14.1 Pathway Genomics Company Detail
11.14.2 Pathway Genomics Business Overview
11.14.3 Pathway Genomics Direct-to-consumer Disease Risk and Health Test Introduction
11.14.4 Pathway Genomics Revenue in Direct-to-consumer Disease Risk and Health Test Business (2019-2024)
11.14.5 Pathway Genomics Recent Development
11.15 Centrillion Technology
11.15.1 Centrillion Technology Company Detail
11.15.2 Centrillion Technology Business Overview
11.15.3 Centrillion Technology Direct-to-consumer Disease Risk and Health Test Introduction
11.15.4 Centrillion Technology Revenue in Direct-to-consumer Disease Risk and Health Test Business (2019-2024)
11.15.5 Centrillion Technology Recent Development
11.16 Xcode
11.16.1 Xcode Company Detail
11.16.2 Xcode Business Overview
11.16.3 Xcode Direct-to-consumer Disease Risk and Health Test Introduction
11.16.4 Xcode Revenue in Direct-to-consumer Disease Risk and Health Test Business (2019-2024)
11.16.5 Xcode Recent Development
11.17 Color Genomics
11.17.1 Color Genomics Company Detail
11.17.2 Color Genomics Business Overview
11.17.3 Color Genomics Direct-to-consumer Disease Risk and Health Test Introduction
11.17.4 Color Genomics Revenue in Direct-to-consumer Disease Risk and Health Test Business (2019-2024)
11.17.5 Color Genomics Recent Development
11.18 Anglia DNA Services
11.18.1 Anglia DNA Services Company Detail
11.18.2 Anglia DNA Services Business Overview
11.18.3 Anglia DNA Services Direct-to-consumer Disease Risk and Health Test Introduction
11.18.4 Anglia DNA Services Revenue in Direct-to-consumer Disease Risk and Health Test Business (2019-2024)
11.18.5 Anglia DNA Services Recent Development
11.19 African Ancestry
11.19.1 African Ancestry Company Detail
11.19.2 African Ancestry Business Overview
11.19.3 African Ancestry Direct-to-consumer Disease Risk and Health Test Introduction
11.19.4 African Ancestry Revenue in Direct-to-consumer Disease Risk and Health Test Business (2019-2024)
11.19.5 African Ancestry Recent Development
11.20 Canadian DNA Services
11.20.1 Canadian DNA Services Company Detail
11.20.2 Canadian DNA Services Business Overview
11.20.3 Canadian DNA Services Direct-to-consumer Disease Risk and Health Test Introduction
11.20.4 Canadian DNA Services Revenue in Direct-to-consumer Disease Risk and Health Test Business (2019-2024)
11.20.5 Canadian DNA Services Recent Development
11.21 DNA Family Check
11.21.1 DNA Family Check Company Detail
11.21.2 DNA Family Check Business Overview
11.21.3 DNA Family Check Direct-to-consumer Disease Risk and Health Test Introduction
11.21.4 DNA Family Check Revenue in Direct-to-consumer Disease Risk and Health Test Business (2019-2024)
11.21.5 DNA Family Check Recent Development
11.22 Alpha Biolaboratories
11.22.1 Alpha Biolaboratories Company Detail
11.22.2 Alpha Biolaboratories Business Overview
11.22.3 Alpha Biolaboratories Direct-to-consumer Disease Risk and Health Test Introduction
11.22.4 Alpha Biolaboratories Revenue in Direct-to-consumer Disease Risk and Health Test Business (2019-2024)
11.22.5 Alpha Biolaboratories Recent Development
11.23 Test Me DNA
11.23.1 Test Me DNA Company Detail
11.23.2 Test Me DNA Business Overview
11.23.3 Test Me DNA Direct-to-consumer Disease Risk and Health Test Introduction
11.23.4 Test Me DNA Revenue in Direct-to-consumer Disease Risk and Health Test Business (2019-2024)
11.23.5 Test Me DNA Recent Development
11.24 23 Mofang
11.24.1 23 Mofang Company Detail
11.24.2 23 Mofang Business Overview
11.24.3 23 Mofang Direct-to-consumer Disease Risk and Health Test Introduction
11.24.4 23 Mofang Revenue in Direct-to-consumer Disease Risk and Health Test Business (2019-2024)
11.24.5 23 Mofang Recent Development
11.25 Genetic Health
11.25.1 Genetic Health Company Detail
11.25.2 Genetic Health Business Overview
11.25.3 Genetic Health Direct-to-consumer Disease Risk and Health Test Introduction
11.25.4 Genetic Health Revenue in Direct-to-consumer Disease Risk and Health Test Business (2019-2024)
11.25.5 Genetic Health Recent Development
11.26 DNA Services of America
11.26.1 DNA Services of America Company Detail
11.26.2 DNA Services of America Business Overview
11.26.3 DNA Services of America Direct-to-consumer Disease Risk and Health Test Introduction
11.26.4 DNA Services of America Revenue in Direct-to-consumer Disease Risk and Health Test Business (2019-2024)
11.26.5 DNA Services of America Recent Development
11.27 Shuwen Health Sciences
11.27.1 Shuwen Health Sciences Company Detail
11.27.2 Shuwen Health Sciences Business Overview
11.27.3 Shuwen Health Sciences Direct-to-consumer Disease Risk and Health Test Introduction
11.27.4 Shuwen Health Sciences Revenue in Direct-to-consumer Disease Risk and Health Test Business (2019-2024)
11.27.5 Shuwen Health Sciences Recent Development
11.28 Mapmygenome
11.28.1 Mapmygenome Company Detail
11.28.2 Mapmygenome Business Overview
11.28.3 Mapmygenome Direct-to-consumer Disease Risk and Health Test Introduction
11.28.4 Mapmygenome Revenue in Direct-to-consumer Disease Risk and Health Test Business (2019-2024)
11.28.5 Mapmygenome Recent Development
11.29 Full Genomes
11.29.1 Full Genomes Company Detail
11.29.2 Full Genomes Business Overview
11.29.3 Full Genomes Direct-to-consumer Disease Risk and Health Test Introduction
11.29.4 Full Genomes Revenue in Direct-to-consumer Disease Risk and Health Test Business (2019-2024)
11.29.5 Full Genomes Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’